A new galenic formulation of selegiline (Xilopae) in the treatment of Parkinson disease

Selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). Selegiline is looked upon as a putative progression of Parkinson's disease (PD) delaying compound due to its in preclinical research proven neuroprotective modes of action. Xilopar(R) is a new formulation of selegiline, which facilitates absorption in the mouth and thus avoids hepatic first-pass metabolism. Intake of 1.25 mg Xilopar(R) provides similar pharmacokinetic plasma behaviour corresponding to oral administration of 10 mg conventional selegiline. This observational trial evaluated the efficacy, safety and tolerability of Xilopar(R) in the daily practice. Motor symptoms and fluctuations of PD patients improved after 3 months of initial treatment with Xilopar(R) or switch from selegiline to Xilopar(R). Both treatment strategies enabled a reduction of the daily oral levodopa intake (initial treatment with Xilopar(R): 21%; 143 +/- 115 [mean +/- SD] mg/daily; pre-treatment with selegiline: 17%; 98 +/- 40 mg/daily). There were no safety or tolerability problems. The results of this observational trial confirm the clinical efficacy, tolerability and safety of Xilopar(R), respectively conventional selegiline formulations in the treatment of PD.     «

Selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). Selegiline is looked upon as a putative progression of Parkinson's disease (PD) delaying compound due to its in preclinical research proven neuroprotective modes of action. Xilopar(R) is a new formulation of selegiline, which facilitates absorption in the mouth and thus avoids hepatic first-pass metabolism. Intake of 1.25 mg Xilopar(R) provides similar pharmacokinetic plasma behaviour corresponding to oral admin...     »